Tredje AP fonden continued to hold its stake in shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 909,581 shares of the biotechnology company’s stock at the close of the second quarter. Tredje AP fonden owned about 2.57% of Strongbridge Biopharma PLC worth $6,504,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in SBBP. State of Wisconsin Investment Board bought a new position in Strongbridge Biopharma PLC in the second quarter worth approximately $114,000. Rhumbline Advisers bought a new position in Strongbridge Biopharma PLC in the second quarter worth approximately $154,000. Bank of New York Mellon Corp bought a new position in Strongbridge Biopharma PLC in the second quarter worth approximately $331,000. Schwab Charles Investment Management Inc. bought a new position in Strongbridge Biopharma PLC in the second quarter worth approximately $332,000. Finally, Broadfin Capital LLC boosted its holdings in Strongbridge Biopharma PLC by 3.0% in the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock worth $14,163,000 after acquiring an additional 87,125 shares in the last quarter. Institutional investors and hedge funds own 63.65% of the company’s stock.
SBBP has been the topic of a number of recent research reports. Oppenheimer Holdings, Inc. initiated coverage on Strongbridge Biopharma PLC in a report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 target price on the stock. Zacks Investment Research lowered Strongbridge Biopharma PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, ValuEngine upgraded Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $11.94.
Strongbridge Biopharma PLC (SBBP) opened at 7.55 on Friday. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85. The stock has a 50 day moving average price of $6.81 and a 200-day moving average price of $5.43. The company’s market cap is $266.78 million.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.84 million. On average, analysts predict that Strongbridge Biopharma PLC will post ($2.48) EPS for the current fiscal year.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with our FREE daily email newsletter.